odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
7778
10.69690/ODMJ-001-0826-7778
Original Research
Real-World Patterns of Immune-Related Toxicity in Gastrointestinal Cancer Patients Treated with Immunotherapy: A service evaluation
Espinosa
Laura Collantes
The Royal Marsden NHS Foundation Trust, London, UK.
laucollantes@gmail.com
https://orcid.org/0000-0002-9889-1248
Czuber-Dochan
Wladzia
Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King’s College London
https://orcid.org/0000-0002-7678-859X
Muls
Ann
The Royal Marsden NHS Foundation Trust, London, UK.
27
08
2026
ODMJ-001-0826-7778
Copyright (c) 2026 OncoDaily Medical Journal
2026
OncoDaily Medical Journal
Gastrointestinal cancer
Oncology Nursing
production-ready-file-url
[
Ghemrawi R, Abuamer L, Kremesh S, et al. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines. 2024;12(9):2158.
]
[
Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev. 2020;88:102030.
]
[
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
]
[
Li M, Cao S, Xu RH. Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer Commun (Lond). 2025;45(7):774-788.
]
[
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
]
[
Andre T, Elez E, Lenz HJ, et al. First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW. J Clin Oncol. 2025;43(4 Suppl).
]
[
Burris HA, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626-635
]
[
Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448-457.
]
[
Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(7):1470-1491.
]
[
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905.
]
[
Oh DY, He AR, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8).
]
[
Chong X, Madeti Y, Cai J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol. 2024;17(1):65.
]
[
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-574.
]
[
Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392.
]
[
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768.
]
[
Ghisoni E, Wicky A, Bouchaab H, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153-164.
]
[
Andreyev J, Adams R, Bornschein J, et al. British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer. Gut. 2025;74(7):1040-1067.
]
[
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126.
]
[
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]. Bethesda (MD): National Cancer Institute; 2017 [cited 2024 Apr 22].
]
[
Usborne CM, Mullard AP. A review of systemic anticancer therapy in disease palliation. Br Med Bull. 2018;125(1):43-53.
]
[
Siddiqui MA, Usmani A, Ansari MN, Almoselhy RIM. Immune-related adverse events in immunotherapy: Challenges in diagnosis, monitoring, and management. Toxicol Rep. 2025;14:102036.
]
[
Pozas J, Cheruvu S, Jaganathan PP, et al. Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study. Cancers (Basel). 2025;17(15):2461.
]
[
Nursing and Midwifery Council. Standards of proficiency for nurses [Internet]. London: Nursing and Midwifery Council; 2024 [cited 2026 Apr 2].
]
[
Teixeira-Poit SM, Sawicki K, O’Kelley W, et al. Efficacy of a Patient Education Session for Cancer Patients Receiving Immunotherapy. Semin Oncol Nurs. 2023;39(4):151445.
]
[
Collantes Espinosa L, Da Costa Mendes C. Management of immune-related adverse events in oncology settings. Cancer Nurs Pract. 2024.
]
[
Royal College of Nursing. RCN Professional Development Framework – Advanced Level Nursing [Internet]. London: Royal College of Nursing; 2024 [cited 2026 Apr 2].
]
[
Diez De Los Rios De La Serna C, Boers-Doets CB, Wiseman T, Radia B, Hammond R. Early Recognition and Management of Side Effects Related to Systemic Anticancer Therapy for Advanced Breast Cancer. Semin Oncol Nurs. 2024;40(1):151553.
]
[
Health Education England. Multiprofessional framework for Advanced Practice in England [Internet]. London: Health Education England; 2025 [cited 2026 Apr 2].
]
[
Lasa-Blandon M, Stasi K, Hehir A, Fischer-Cartlidge E. Patient Education Issues and Strategies Associated With Immunotherapy. Semin Oncol Nurs. 2019;35(5):150933.
]
[
Mirzadeh P, Pituskin E, Au I, Sneath S, Buick CJ. Cancer Immunotherapy: The Role of Nursing in Patient Education, Assessment, Monitoring, and Support. Curr Oncol. 2025;32(7):392.
]
[
Watts T, Roche D, Csontos J. Patients’ experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis. J Clin Nurs. 2024;jocn.17154.
]
[
Barrott L, Wiseman T, Tsianakas V, Czuber-Dochan W. Nurse and pharmacist systemic anti-cancer therapy review clinics and their impact on patient experience and care: A systematic review. J Adv Nurs. 2023;79(2):442-453.
]